Since the first humanized monoclonal antibody (mAb), trastuzumab, was approved by the Food and Drug Administration (FDA) for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, an increasing number of patients have received mAb therapy and prolonged their survival (Adams and Weiner, 2005). The gene discussed is ERBB2; the disease is breast cancer.